삼중음성유방암(TNBC) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2026-2036년)

Triple-Negative Breast Cancer Market Outlook and Forecast

Thelansis's "Triple-Negative Breast Cancer (TNBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Triple-Negative Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Triple-Negative Breast Cancer Overview

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by absent estrogen receptor, progesterone receptor, and HER2 expression. Its heterogeneity, early recurrence risk, and metastatic potential complicate treatment. For stage II-III disease, neoadjuvant chemotherapy remains a core treatment, with pembrolizumab-based chemoimmunotherapy improving outcomes. In metastatic disease, treatment is guided by PD-L1 status, prior therapy, germline BRCA status, and other biomarkers. PARP inhibitors are used for germline BRCA1/2-mutated disease, while antibody-drug conjugates have expanded treatment options. In 2026, the FDA approved sacituzumab govitecan for first-line unresectable locally advanced or metastatic TNBC, alone for patients not eligible for PD-1/PD-L1 therapy and with pembrolizumab for PD-L1-positive disease. Development continues across ADCs, immune therapies, DNA-repair targets, and biomarker-defined strategies, with resistance and durable control key challenges.

Key Highlights

• In Spain, TNBC incident cases are projected to increase from 2,778 in 2026 to 2,899 by 2036.
• TNBC is an aggressive breast cancer subtype with limited targeted treatment options.
• Higher risk of recurrence and metastasis remains a major clinical challenge.
• Significant unmet need remains for durable and effective treatment options.

Market Overview

• The Germany TNBC market is projected to grow from $330M in 2026 to $785M by 2036.
• Market growth is driven by:
• Increasing adoption of immunotherapy and targeted treatment approaches
• Continued development of novel TNBC therapies
• Future growth will depend on therapies that improve durable responses and long-term outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AstraZeneca
• Merck Sharp & Dohme LLC
• Seagen Inc.
• Hoffmann-La Roche
• Telomir Pharmaceuticals, Inc.
• Cantargia AB
• Gilead Sciences
• Jina Pharmaceuticals Inc.
• BioLite, Inc.
• OBI Pharma, Inc.
• SURGE Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Akeso
• BioNTech SE
• CoRegen, Inc.
• MedSIR
• Beijing Biotech
• Adcentrx Therapeutics
• NiKang Therapeutics, Inc.
• Pfizer
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• Novartis Pharmaceuticals
• Accent Therapeutics
• SillaJen, Inc.
• Apollo Therapeutics Ltd
• Radiopharm Theranostics, Ltd.
• Normunity AccelCo, Inc.
• Genentech, Inc.
• AbbVie
• Genmab
• IDEAYA Biosciences
• Arcus Biosciences, Inc.
• Immunitas Therapeutics
• Exelixis
• Incyte Corporation
• OncoNano Medicine, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)